NEW YORK (AP) -- Japanese drugmaker Takeda is ending research on its type 2 diabetes drug fasiglifam because of concerns about its effects on patients' livers.
Takeda said Thursday that it has evaluated data from clinical trials of the drug and consulted with experts, concluding that the benefits of treating patients with fasiglifam don't outweigh the risks. The company was conducting late-stage studies of the drug.
Takeda Pharmaceutical Co. said it will continue studying potential treatment for diabetes.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.